DNTH – dianthus therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Dianthus Therapeutics (DNTH) was upgraded by Wolfe Research to "strong-buy".
Dianthus Therapeutics (DNTH) is now covered by Wolfe Research. They set an "outperform" rating and a $98.00 price target on the stock.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics CFO Sells $9.5 Million in Stock [Yahoo! Finance]
How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart [Yahoo! Finance]
Form 4 Dianthus Therapeutics, For: Apr 09 Filed by: Savitz Ryan
Form 144 Dianthus Therapeutics, Filed by: Savitz Ryan
Form ARS Dianthus Therapeutics, For: Dec 31
Form DEFA14A Dianthus Therapeutics,
Form DEF 14A Dianthus Therapeutics, For: May 21
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.